◀ Back to PCNA
HDAC1 — PCNA
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Biogrid Interaction:
PCNA
—
HDAC1
(physical association, affinity chromatography technology)
Milutinovic et al., J Biol Chem 2002*
-
IRef Biogrid Interaction:
PCNA
—
HDAC1
(direct interaction, pull down)
Milutinovic et al., J Biol Chem 2002*
-
IRef Biogrid Interaction:
PCNA
—
HDAC1
(physical association, affinity chromatography technology)
Naryzhny et al., J Biol Chem 2004*
-
IRef Hprd Interaction:
PCNA
—
HDAC1
(in vivo)
Milutinovic et al., J Biol Chem 2002*
-
IRef Hprd Interaction:
PCNA
—
HDAC1
(in vitro)
Milutinovic et al., J Biol Chem 2002*
-
IRef Intact Interaction:
Complex of 400 proteins
(association, cross-linking study)
Humphries et al., Science signaling 2009
-
IRef Ophid Interaction:
PCNA
—
HDAC1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
-
IRef Ophid Interaction:
PCNA
—
HDAC1
(aggregation, confirmational text mining)
Milutinovic et al., J Biol Chem 2002*
Text-mined interactions from Literome
Hatjiharissi et al., Cancer Res 2007
(Waldenstrom Macroglobulinemia) :
Other proteins up-regulated by > 1.3-fold included
cyclin dependent kinases, apoptosis regulators, and
histone deacetylases (HDAC)
Veliz et al., Cancer Control 2012
(Leukemia, Lymphocytic, Chronic, B-Cell...) :
These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab,
cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors, and
histone deacetylase inhibitors
Brett et al., Current treatment options in oncology 2013
:
Similarly, cell cycle inhibitors targeting
cyclin dependent kinases as well as
HDAC inhibitors have shown promise in early studies